Genk, Belgium, September 14th 2006 -- A new radiotherapy center that will provide patients in the north-east of Belgium with greater access to advanced cancer treatments will be equipped with Varian Medical Systems’ integrated and automated treatment equipment and software, it has been announced. The new center will be capable of offering patients the latest in highly-targeted radiotherapy treatments, including intensity modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT) and stereotactic radiosurgery (SRS).
The new department, currently being built in the Ziekenhuis Oost Limburg at Genk and due to take its first patients in April 2007, will operate as part of the Limburg Oncology Centre, a collaboration between the two hospitals in nearby Hasselt and the Ziekenhuis Oost Limburg. It will share medical staff with Hasselt but will be more convenient for nearby patients who need to visit for daily treatments. Both centers will use integrated software to offer patients faster, more automated and more comfortable treatments. The new facility will serve about half the province (about 800,000) in the north-east of Limburg and is expected to treat up to 800 patients in the first year.
An order has been placed for two Varian Clinac® linear accelerators at the new department in Genk and for a third Varian accelerator that will replace an older machine at Hasselt.
Dr. Paul Bulens, medical director at the Limburg Oncology Centre, said, “The key challenge for us is to make the Hasselt and Genk sites effectively one big center and we needed a supplier who could handle that level of integration. Doctors will travel regularly between the two sites and we want complete integration between the two.‿
As well as treatment machines, both sites will have Varian’s ARIA™ information and image management system and Eclipse™ treatment planning systems, enabling a rapid and highly integrated flow of patient information and treatment plans across the network.
“The full integration of both sites into one big center avoids a fractionation into small radiotherapy departments while enabling the latest radiotherapy treatments to be offered,‿ said Vincent Ronfle, Varian’s regional sales manager. “This order shows that we are able to meet their demanding requirements for modern cancer treatments.‿ He pointed out that Varian supports a similar network at Wilrijk in Belgium, where treatment machines based in a satellite facility are managed remotely and other manufacturers’ equipment works seamlessly with Varian’s information management system.
Dr. Bulens said the third Varian Clinac acquired as part of this project will replace an ageing accelerator at Hasselt as soon as the two machines are installed at Genk. Hasselt’s two other accelerators are due to be replaced over coming years as the center seeks to standardize across the Limburg province.
Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068
About Varian Medical Systems Forward Looking Statements
Varian Medical Systems, Inc., of Palo Alto, California is the world's leading manufacturer of medical technology for treating cancer with radiotherapy and neurological conditions with radiosurgery. The company is also a premier supplier of X-ray tubes and flat-panel digital subsystems for imaging in medical, scientific, and industrial applications. Varian Medical Systems employs approximately 3,600 people who are located at manufacturing sites in North America and Europe and in its 56 sales and support offices around the world. In Europe, the company operates manufacturing and engineering centers in Baden (Switzerland), Crawley (England), Haan (Germany), Helsinki (Finland) and Toulouse (France) and has headquarters for Europe, Middle East, India and Africa (EMEA) based in Zug, Switzerland.Additional information is available on the company's web site at http:/pt-pt//pt-pt/www.varian.com/pt-pt/
Statements in this press release regarding future business, events, plans, objectives, expectations, estimates, and other similar matters, including, but not limited to, statements using the terms "can" and "expect," constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to, the risks described in the Company's Annual Report on Form 10-K and other reports filed from time to time by the Company with the U.S. Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company assumes no obligation to update or revise these forward-looking statements because of new information, future events, or otherwise. Furthermore, notwithstanding any specific events announced in this press release, the Company's quarterly and annual financial results are subject to such risks and uncertainties described in the Company's Annual Report on Form 10-K and other reports filed from time to time by the Company with the U.S. Securities and Exchange Commission and actual results may differ materially from those anticipated.
Forward Looking Statements